Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Genomic Health presents 11 studies demonstrating value of Oncotype DX breast cancer test

Genomic Health presents 11 studies demonstrating value of Oncotype DX breast cancer test

Genomic Health today announced the presentation of 11 studies with the Oncotype DX breast cancer test at the 14th St. Gallen Breast Cancer Conference in Vienna, Austria. Studies presented include results from a real-life observational study in Ireland demonstrating significant reductions in chemotherapy and resulting cost savings when the test is used in early stage breast cancer. [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T. [More]
MRD-directed therapy helps boost survival of young leukemia patients

MRD-directed therapy helps boost survival of young leukemia patients

Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy should help boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. St. Jude Children's Research Hospital investigators led the research, which appears in the March 20 edition of the journal Lancet Oncology. [More]
New article highlights the problem of antibiotic use in lab experiments

New article highlights the problem of antibiotic use in lab experiments

Scientists should reduce antibiotic use in lab experiments - according to a researcher at the University of East Anglia. [More]
Scientists discover how ALL cells mutate to survive chemotherapy

Scientists discover how ALL cells mutate to survive chemotherapy

By genomic sequencing of leukemia cells from relapsed patients at different stages, scientists have discovered key details of how acute lymphoblastic leukemia (ALL) cells mutate to survive chemotherapy. These mutations enable the cells to proliferate, causing relapse and often death. [More]
Targeted drug doubles progression free survival in Hodgkin lymphoma

Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months). [More]
New range of purified, soluble immunoreceptors announced by AMSBIO

New range of purified, soluble immunoreceptors announced by AMSBIO

AMSBIO has announced a new range of purified, soluble immunoreceptors involved in key signalling pathways. Together with new indoleamine 2,3-dioxygenase (IDO) assay kits these products that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies that serve as positive controls for inhibition. [More]
BCM-95 Curcumin improves chemotherapy's effectiveness in killing chemoresistant cancer cells

BCM-95 Curcumin improves chemotherapy's effectiveness in killing chemoresistant cancer cells

Cancer cell resistance to chemotherapy is a major cause of death in patients with colorectal cancer. In a first-of-its-kind study, BCM-95 Curcumin was found to improve chemotherapy's effectiveness in killing chemoresistant cells via a mechanism not previously identified. [More]
Sigma-Aldrich, Roche sign distribution agreement for Biochemical Reagents products

Sigma-Aldrich, Roche sign distribution agreement for Biochemical Reagents products

Sigma-AldrichCorporation, a leading Life Science and Technology company, announced today it signed an exclusive global distribution agreement with Roche. The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich. [More]
Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers identify MG53 protein necessary for repairing injured kidney cells

Cardiovascular researchers at The Ohio State University Wexner Medical Center have shown that a protein known as MG53 is not only present in kidney cells, but necessary for the organ to repair itself after acute injury. Results from this animal model study are published in the journal Science Translational Medicine. [More]
IU researchers reveal how Toxoplasma parasites modify brain cells

IU researchers reveal how Toxoplasma parasites modify brain cells

Rodents infected with a common parasite lose their fear of cats, resulting in easy meals for the felines. Now IU School of Medicine researchers have identified a new way the parasite may modify brain cells, possibly helping explain changes in the behavior of mice -- and humans. [More]
New microarray-based tool provides fast, reliable assessment of vaginal health

New microarray-based tool provides fast, reliable assessment of vaginal health

A new microarray-based tool, called VaginArray, offers the potential to provide a fast, reliable and low-cost assessment of vaginal health and diagnoses of infections. The research is published ahead of print March 2, in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology. [More]
New radiation treatment for brain cancer implanted in first human being at CTRC

New radiation treatment for brain cancer implanted in first human being at CTRC

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor. [More]
NCCN panelists discuss on evidence-based decision-making at bedside

NCCN panelists discuss on evidence-based decision-making at bedside

On Friday, March 13, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care, the National Comprehensive Cancer Network hosted its second roundtable, Value-Based Decision-Making at the Bedside, which reflected on the tools available to oncology clinicians, such as clinical practice guidelines and pathways, and how the use of these tools has impacted bedside evidence-based decision-making for both physicians and patients, the criteria used to assess shared decision-making, and the relationship between outcomes and cost when determining value. [More]
Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise. [More]
Researchers find that exercise may slow tumor growth, improve chemotherapy

Researchers find that exercise may slow tumor growth, improve chemotherapy

One way many cancers grow resistant to treatment is by generating a web of blood vessels that are so jumbled they fail to provide adequate oxygen to the tumor. With oxygen starvation, the tumor gains a sort of cloaking device that protects it from the toxic effects of chemotherapy drugs and radiation, which are designed to seek out well-oxygenated tissue. [More]
EMAS position statement on ten-point guide to integral management of menopausal health published

EMAS position statement on ten-point guide to integral management of menopausal health published

Elsevier journal Maturitas, today announced the publication of a position statement by the European Menopause and Andropause Society covering the ten- point guide to the integral management of menopausal health. [More]
CTCA in Philadelphia installs TomoHDA TomoTherapy machine to provide precise treatment to patients

CTCA in Philadelphia installs TomoHDA TomoTherapy machine to provide precise treatment to patients

Cancer Treatment Centers of America in Philadelphia has announced the installation of the TomoHDA TomoTherapy machine. TomoTherapy combines an advanced form of intensity modulated radiation therapy (IMRT), with the accuracy of computed tomography (CT) scanning technology, all in one machine. [More]
Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

Novimmune SA announces that patients diagnosed with hemophagocytic lymphohistiocytosis (HLH), and who are participating in the company's ongoing clinical trial of its NI-0501 monoclonal antibody, will now be able to be treated with the drug without having to first fail conventional treatments. [More]
Advertisement
Advertisement